Alignment Healthcare Q4 Earnings Announced: Revenue Growth and Future Projections
Alignment Healthcare (NASDAQ:ALHC) announced its impressive fourth-quarter 2025 earnings, reflecting a robust 44.4% increase in revenue from the previous year, reaching $1.01 billion. This figure surpassed Wall Street's expectations. However, the forecast for the upcoming quarter projects revenue at $1.22 billion, slightly under analysts' expectations by 1.9%. The company achieved a GAAP loss per share of $0.05, outperforming consensus estimates by 67.1%.
Founded in 2013, Alignment Healthcare specializes in Medicare Advantage plans for seniors, with a keen focus on concierge care and AI-driven technology coordination. Over the past five years, the firm has maintained an impressive annual sales growth rate of 32.7%, suggesting a strong consumer demand for its services. Notably, its recent two-year annualized revenue growth rate of 47.1% highlights accelerating demand.
During the latest quarter, Alignment Healthcare served 236,300 customers, marking an average annual growth rate of 25.5% in customer numbers over two years. This growth suggests a rising annual spending per customer. In this quarter, it achieved 44.4% revenue growth, surpassing market expectations by 1%. Management anticipates a 31.1% increase in sales in the upcoming quarter.
Looking forward, analysts predict a 31.2% growth in revenue over the next year, though slightly slower than the past two-year trajectory. Despite challenges with expense management, evidenced by a negative average operating margin of 4.7% over the last five years, Alignment Healthcare has enhanced its operational efficiency, improving margins by 15.6 percentage points recently, with a 7.4% improvement over two years.
Currently, the company's operating margin sits at negative 1%, but there has been significant progress in earnings per share (EPS), which has improved from negative to breakeven over five years. In the fourth quarter, the EPS was negative $0.05, compared to negative $0.16 a year ago, exceeding analyst forecasts. Projections indicate the EPS could turn positive to $0.10 within the next year.
Despite surpassing EPS forecasts and achieving slightly higher revenue targets this quarter, Alignment Healthcare's guidance for next quarter's revenue and EBITDA fell short of analysts' predictions. This led to a 4.5% decrease in the company’s stock price to $19.50. As investors weigh their options, a comprehensive evaluation of recent financial results and the company's market valuation is essential.